Condition: Acute Myeloid Leukemia Refractory · Acute Myeloid Leukemia, in Relapse · Myelodysplastic Syndrome Acute Myeloid Leukemia · Sponsor: AB Science
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
This description comes directly from the study's public registry record.
Clinical Study Coordinator · +33(0)147200014 · clinical@ab-science.com
Always discuss trial participation with your own doctor first.
| MD Anderson Cancer Center | Houston, Texas, United States | Not Yet Recruiting |
| Institut Paoli Calmettes | Marseille, France | Not Yet Recruiting |
| National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit | Athens, Greece | Recruiting |
| General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante) | Alicante, Spain | Recruiting |
| Hospital San Pedro de Alcantara | Cáceres, Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Spain | Recruiting |
| Hospital Universitario Quirónsalud | Madrid, Spain | Recruiting |
| MD Anderson Cancer Center Madrid | Madrid, Spain | Recruiting |
| Clínica Universidad de Navarra | Pamplona, Spain | Recruiting |
| Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío) | Seville, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05211570